Publications by authors named "L E Boos"

Article Synopsis
  • A study on the combination of ipilimumab (ipi) and nivolumab (nivo) for treating malignant pleural mesothelioma (MPM) in Switzerland revealed real-world survival and safety data, confirming its status as a standard-of-care after positive clinical trial results (CheckMate-743).
  • Among the 109 patients treated from November 2017 to March 2023, the objective response rate to ipi-nivo was 21% for first-line treatment and 15% for second or further-line treatments, with median overall survival being 12.6 months for first-line and 6.9 months for second-line.
  • The treatment was generally well-t
View Article and Find Full Text PDF

Aim: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for patients with EGFR mutated non-small cell lung cancer as first-line treatment. However, treatment resistance inevitably emerges and may present as oligo-progressive disease (OPD) or systemic progressive disease (SPD). The incidence of OPD on first-line osimertinib is unknown.

View Article and Find Full Text PDF

Advanced triple negative breast cancer (TNBC) is an aggressive, but initially chemo-sensitive disease. The prognosis is poor and more than three quarters of patients experience progression 12 months after the initiation of conventional first-line chemotherapy. Approximately two thirds of TNBC express epidermal growth factor receptor 1 (EGFR).

View Article and Find Full Text PDF
Article Synopsis
  • * Out of those tested, 118 had COVID-19, with 94 showing symptoms and only 2 fatalities, revealing high levels of S1-reactive and neutralizing antibodies against the virus.
  • * Immune responses varied, particularly with hematological cancer patients showing unique challenges but still managing clinical recovery, highlighting the need for more research on immune durability against different SARS-CoV-2 variants.
View Article and Find Full Text PDF
Article Synopsis
  • The CAPTURE study evaluated COVID-19 immunity in 585 cancer patients after receiving two doses of either BNT162b2 or AZD1222 vaccines, revealing seroconversion rates of 85% for those with solid tumors and 59% for those with hematological malignancies.
  • Patients with hematological cancers had significantly lower levels of detectable neutralizing antibodies (NAbT) against SARS-CoV-2 variants compared to those with solid tumors and healthy individuals.
  • Previous COVID-19 infections increased NAb responses, particularly against variants, but treatment with anti-CD20 medications correlated with undetectable NAbT, highlighting important considerations for cancer patient management during the pandemic.
View Article and Find Full Text PDF